Operator: Good day, and thank you for standing by. Welcome to the Adaptive Biotechnologies Second Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode.
The test, which assesses predictive blood-based biomarkers and electronic health record data, was first introduced in the US in late 2020 as a laboratory-developed test.
MDxHealth SA, a maker of noninvasive urology tests used to diagnose prostate cancer that’s struggled to gain traction as a public company (Nasdaq: MDXH), looks closer to turning an important corner.